Formosa Pharmaceuticals in Taiwan has signed an exclusive licensing agreement with Medvisis Switzerland to commercialise clobetasol propionate ophthalmic suspension, 0.05% (APP13007), for post-operative inflammation and pain after ocular surgery.

The agreement grants Medvisis exclusive rights for the therapy in Switzerland and Liechtenstein.

APP13007 received approval from the US Food and Drug Administration in March 2024.

The deal between Formosa and Medvisis includes upfront payments, sales milestones and additional considerations throughout the term period.

Formosa Pharmaceuticals CEO and president Erick Co stated: “We are pleased to partner with Medvisis, marking our second foothold in Europe.

“Medvisis’ strong connections with their national regulatory agency and rich KOL [key opinion leaders] network give us great confidence that the Swiss public will benefit from this novel and effective treatment for ocular surgery recovery.”

APP13007 features the active ingredient superpotent corticosteroid clobetasol propionate, and is based on Formosa’s APNT [active pharmaceutical nanotechnology] nanoparticle formulation platform.

The therapy’s formulation allows for a twice-daily dosing regimen for 14 days, providing rapid and sustained relief. It was launched in the US market in September 2024.

A US survey of 100 ophthalmic surgeons highlighted the rapid resolution of pain, with 80% of patients pain-free four days post-surgery, and a low incidence of adverse events, less than 2%, as key factors.

In August 2024, Formosa signed an exclusive licencing agreement with Apotex for the commercialisation of APP13007.

Medvisis Switzerland CEO Manuel Ackermann stated: “We are pleased to provide patients with post-operative inflammation and pain following ocular surgery a new, best-in-class treatment option that leads to faster symptom relief.

“APP13007 is of great value to Swiss patients, while it sets the foundation for Medvisis to build a strong portfolio of innovative ophthalmology solutions.”